Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial - 23/02/18
, Isabelle Charreau, MD f, Christian Chidiac, ProfMD h, Gilles Pialoux, ProfMD i, Eric Cua, MD j, Constance Delaugerre, ProfPhD b, d, Catherine Capitant, MD f, Daniela Rojas-Castro, PhD k, Julien Fonsart, PharmD c, Béatrice Bercot, MD b, e, Cécile Bébéar, ProfMD l, Laurent Cotte, MD h, Olivier Robineau, MD m, François Raffi, ProfMD n, Pierre Charbonneau, ProfMD a, Alexandre Aslan, MD a, Julie Chas, MD i, Laurence Niedbalski, BS a, Bruno Spire, PhD o, Luis Sagaon-Teyssier, PhD o, Diane Carette, PhD f, Soizic Le Mestre, MSc p, Veronique Doré, PhD p, Laurence Meyer, ProfMD f, gfor the
ANRS IPERGAY Study Group†
Summary |
Background |
Increased rates of sexually transmitted infections (STIs) have been reported among men who have sex with men. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of STIs.
Methods |
All participants attending their scheduled visit in the open-label extension of the ANRS IPERGAY trial in France (men aged 18 years or older having condomless sex with men and using pre-exposure prophylaxis for HIV with tenofovir disoproxil fumarate plus emtricitabine) were eligible for inclusion in this open-label randomised study. Participants were randomly assigned (1:1) at a central site to take a single oral dose of 200 mg doxycycline PEP within 24 h after sex or no prophylaxis. The primary endpoint was the occurrence of a first STI (gonorrhoea, chlamydia, or syphilis) during the 10-month follow-up. The cumulative probability of occurrence of the primary endpoint was estimated in each group with the Kaplan-Meier method and compared with the log-rank test. The primary efficacy analysis was done on the intention-to-treat population, comprising all randomised participants. All participants received risk-reduction counselling and condoms, and were tested regularly for HIV. This trial is registered with ClinicalTrials.gov number, NCT01473472.
Findings |
Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=116 in the no-PEP group) who were followed up for a median of 8·7 months (IQR 7·8–9·7). Participants in the PEP group used a median of 680 mg doxycycline per month (IQR 280–1450). 73 participants presented with a new STI during follow-up, 28 in the PEP group (9-month probability 22%, 95% CI 15–32) and 45 in the no-PEP group (42%, 33–53; log-rank test p=0·007). The occurrence of a first STI in participants taking PEP was lower than in those not taking PEP (hazard ratio [HR] 0·53; 95% CI 0·33–0·85; p=0·008). Similar results were observed for the occurrence of a first episode of chlamydia (HR 0·30; 95% CI 0·13–0·70; p=0·006) and of syphilis (0·27; 0·07–0·98; p=0·047); for a first episode of gonorrhoea the results did not differ significantly (HR 0·83; 0·47–1·47; p=0·52). No HIV seroconversion was observed, and 72 (71%) of all 102 STIs were asymptomatic. Rates of serious adverse events were similar in the two study groups. Gastrointestinal adverse events were reported in 62 (53%) participants in the PEP group and 47 (41%) in the no-PEP group (p=0·05).
Interpretation |
Doxycycline PEP reduced the occurrence of a first episode of bacterial STI in high-risk men who have sex with men.
Funding |
France Recherche Nord & Sud Sida-HIV Hépatites (ANRS) and Bill & Melinda Gates Foundation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 18 - N° 3
P. 308-317 - mars 2018 Retour au numéro
Article précédent
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
- Benoit Guery, Francesco Menichetti, Veli-Jukka Anttila, Nicholas Adomakoh, Jose Maria Aguado, Karen Bisnauthsing, Areti Georgopali, Simon D Goldenberg, Andreas Karas, Gbenga Kazeem, Chris Longshaw, Jose Alejandro Palacios-Fabrega, Oliver A Cornely, Maria J G T Vehreschild, EXTEND Clinical Study Group
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- Evelina Tacconelli, Elena Carrara, Alessia Savoldi, Stephan Harbarth, Marc Mendelson, Dominique L Monnet, Céline Pulcini, Gunnar Kahlmeter, Jan Kluytmans, Yehuda Carmeli, Marc Ouellette, Kevin Outterson, Jean Patel, Marco Cavaleri, Edward M Cox, Chris R Houchens, M Lindsay Grayson, Paul Hansen, Nalini Singh, Ursula Theuretzbacher, Nicola Magrini, WHO Pathogens Priority List Working Group, Aaron Oladipo Aboderin, Seif Salem Al-Abri, Nordiah Awang Jalil, Nur Benzonana, Sanjay Bhattacharya, Adrian John Brink, Francesco Robert Burkert, Otto Cars, Giuseppe Cornaglia, Oliver James Dyar, Alex W Friedrich, Ana C Gales, Sumanth Gandra, Christian Georg Giske, Debra A Goff, Herman Goossens, Thomas Gottlieb, Manuel Guzman Blanco, Waleria Hryniewicz, Deepthi Kattula, Timothy Jinks, Souha S Kanj, Lawrence Kerr, Marie-Paule Kieny, Yang Soo Kim, Roman S Kozlov, Jaime Labarca, Ramanan Laxminarayan, Karin Leder, Leonard Leibovici, Gabriel Levy-Hara, Jasper Littman, Surbhi Malhotra-Kumar, Vikas Manchanda, Lorenzo Moja, Babacar Ndoye, Angelo Pan, David L Paterson, Mical Paul, Haibo Qiu, Pilar Ramon-Pardo, Jesús Rodríguez-Baño, Maurizio Sanguinetti, Sharmila Sengupta, Mike Sharland, Massinissa Si-Mehand, Lynn L Silver, Wonkeung Song, Martin Steinbakk, Jens Thomsen, Guy E Thwaites, Jos WM van der Meer, Nguyen Van Kinh, Silvio Vega, Maria Virginia Villegas, Agnes Wechsler-Fördös, Heiman Frank Louis Wertheim, Evelyn Wesangula, Neil Woodford, Fidan O Yilmaz, Anna Zorzet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?